The Center for Radiopharmaceutical Sciences (CRS), a joint research center of ETH Zurich and Paul Scherrer Institute (PSI), is internationally recognized for pioneering research in radiopharmaceutical chemistry and targeted radionuclide therapy. The Schibli Group develops innovative radiopharmaceuticals for the diagnosis and treatment of cancer and other severe diseases. This newly funded interdisciplinary ETH research project is conducted in close collaboration with the laboratory of Prof. Kaspar Locher (Department of Biology, ETH Zurich). Peptides and nanobodies are highly promising molecules for molecular imaging and targeted therapies, but their clinical translation is often limited by unfavorable pharmacokinetic properties. The project aims to investigate how defined N-glycosylation can improve the biological and pharmacological properties of therapeutic and diagnostic peptides and nanobodies. Novel glycoengineered biomolecules generated in the Locher laboratory will be radiolabeled and systematically evaluated using advanced in vitro and in vivo methodologies established in the Schibli laboratory. The project combines cutting-edge glycobiology, radiopharmaceutical sciences, targeted radionuclide therapy, and translational research.
Dieses Unternehmensprofil wurde automatisch erstellt. Wenn du für ETH Zürich arbeitest, kannst du das Profil jetzt beanspruchen und verifizieren – kostenlos und in wenigen Minuten.
Collaboration within a motivated team characterized by mutual support, individual responsibility, and a constructive feedback culture. Close cooperation with the Locher laboratory and support from experienced colleagues.